Menu
Search
|

Menu

Close
X

BioCryst Pharmaceuticals Inc BCRX.OQ (NASDAQ Stock Exchange Global Select Market)

5.59 USD
-0.18 (-3.12%)
As of Jun 22
chart
Previous Close 5.77
Open 5.77
Volume 623,221
3m Avg Volume 233,962
Today’s High 5.77
Today’s Low 5.35
52 Week High 6.67
52 Week Low 3.95
Shares Outstanding (mil) 98.72
Market Capitalization (mil) 551.83
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.50 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY18
4
FY17
25
FY16
26
FY15
48
EPS (USD)
FY18
-0.261
FY17
-0.779
FY16
-0.749
FY15
-0.593
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.14
Price to Sales (TTM)
vs sector
27.98
8.17
Price to Book (MRQ)
vs sector
8.89
4.30
Price to Cash Flow (TTM)
vs sector
--
22.70
Total Debt to Equity (MRQ)
vs sector
85.75
17.55
LT Debt to Equity (MRQ)
vs sector
28.76
13.12
Return on Investment (TTM)
vs sector
-102.45
13.10
Return on Equity (TTM)
vs sector
-153.78
15.09

EXECUTIVE LEADERSHIP

Robert Ingram
Chairman of the Board, Since 2017
Salary: $17,298.00
Bonus: --
Jon Stonehouse
President, Chief Executive Officer, Director, Since 2007
Salary: $519,828.00
Bonus: --
Thomas Staab
Chief Financial Officer, Senior Vice President, Principal Accounting Officer, Treasurer, Since 2013
Salary: $423,417.00
Bonus: --
Yarlagadda Babu
Senior Vice President - Drug Discovery, Since 2013
Salary: $373,152.00
Bonus: --
Lynne Powell
Senior Vice President, Chief Commercial Officer, Since 2015
Salary: $360,500.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

4505 Emperor Blvd Ste 200
DURHAM   NC   27703-8457

Phone: +1919.8591302

BioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company's drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.

SPONSORED STORIES